Sermorelin vs Tesamorelin: What’s the Difference?

Sermorelin and tesamorelin are both lab-made versions of growth hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. The main difference is size and stability: sermorelin is a short 29-amino-acid fragment of GHRH, while tesamorelin is the full 44-amino-acid hormone with a small chemical “cap” that helps it resist being broken down.

Comparing tesamorelin with a ghrelin-receptor peptide instead? Our plain-English guide to tesamorelin vs ipamorelin explains how the two differ in receptor, size and regulatory status.

That is the quick answer. Below we walk through how the two compare on structure, stability, research history and what to look for on a certificate of analysis, with a side-by-side table if you just want the headlines.

What sermorelin and tesamorelin have in common

Your body makes GHRH in the hypothalamus, a small area at the base of the brain. It travels a short distance to the pituitary gland, where it binds the GHRH receptor on growth hormone-producing cells (somatotrophs) and nudges them to release growth hormone in pulses.

Natural human GHRH is 44 amino acids long. Both sermorelin and tesamorelin are built from that same sequence and act on that same receptor. That is why they turn up together so often in growth hormone research, and why people searching “sermorelin vs tesamorelin” are usually trying to work out what actually separates them.

Sermorelin vs tesamorelin: the key differences

1. Length: 29 vs 44 amino acids

Researchers discovered that you do not need all 44 amino acids of GHRH to switch the receptor on. The first 29 do the job. Sermorelin is exactly that: GHRH(1–29) with an amide group on the end. A detailed review in BioDrugs describes it as the shortest synthetic peptide with the full biological activity of GHRH (Prakash and Goa, 1999).

Tesamorelin keeps all 44 amino acids. So, as a rough rule, sermorelin is the “minimum working piece” and tesamorelin is the “whole hormone, modified”.

2. The cap: why tesamorelin is more stable

Natural GHRH does not last long in blood. An enzyme called dipeptidyl peptidase-4 (DPP-4, sometimes written DPP-IV) snips the first two amino acids off the front, which inactivates it. Sermorelin has the same natural front end, so it is open to the same problem.

Tesamorelin was developed (originally under the code name TH9507) to get around this. A small trans-3-hexenoyl group is attached to the first amino acid, a tyrosine. In non-clinical studies, that change made the peptide resistant to DPP-4, slowed its breakdown in rat, dog and human plasma, and extended how long it stayed in circulation in animals (Ferdinandi et al., 2007).

So when people say tesamorelin is “longer-acting”, this is what they mean: it is a more stable molecule, not a different kind of signal.

3. Size and molecular weight

Because it is longer and capped, tesamorelin is a much heavier molecule. According to the NIH’s PubChem record for tesamorelin, it has the formula C₂₂₁H₃₆₆N₇₂O₆₇S and a molecular weight of about 5,136 Da. Sermorelin’s PubChem entry lists about 3,358 Da. That gap is handy in the lab, as we explain in the COA section below.

4. Research and regulatory history

The two have quite different back stories:

• Sermorelin was one of the first GHRH analogues studied in depth. Much of the early published work looked at it as a diagnostic tool for testing pituitary growth hormone release in children (covered in the 1999 review above). It was once marketed as a medicine under the brand name Geref and has since been discontinued.
• Tesamorelin came later and was studied in large clinical trials in a specific group of people with HIV, including a phase 3 trial published in the New England Journal of Medicine (Falutz et al., 2007). It went on to become a prescription medicine in the United States for that narrow use.

That history is useful context, but it does not mean anything about a research-grade sample. A licensed medicine and a research peptide are different things, made and regulated in different ways.

Side-by-side comparison table

Which one do researchers choose, and why?

It mostly comes down to the question being asked:

• If a study needs something close to the natural signal, short-lived and quickly cleared, sermorelin is the closer match.
• If a study is about stability, or needs GHRH receptor activation to last longer in a model, tesamorelin’s design is the point.
• If the work is about peptide chemistry itself, comparing the two is a neat real-world example of how one small modification can change how a peptide behaves.

Neither is “better” in general. They are tools built for slightly different jobs. If you are weighing up other GHRH-type peptides too, our growth hormone peptides research hub puts them side by side, and our tesamorelin peptide research guide goes deeper on its structure and published research areas.

How to check you have the right peptide: reading the COA

Because the names sound alike and both are white powders in a vial, the certificate of analysis (COA) is your best friend. Look for two things:

1. Identity by mass spectrometry. The measured mass should match the expected molecular weight: around 3,358 Da for sermorelin, around 5,136 Da for tesamorelin. A difference of nearly 1,800 Da is impossible to miss.
2. Purity by HPLC. This tells you what share of the sample is the target peptide. It confirms how clean the material is, not which peptide it is, which is why you need both results.

Our step-by-step guide to reading a peptide certificate of analysis explains each section in plain English. At Peptides UK, both our sermorelin acetate and tesamorelin come with third-party HPLC and COA verification, so you can check identity and purity before any lab work begins.

Have a question about a batch? Email us at research@peptideslabuk.co.uk.

Sermorelin vs tesamorelin FAQ

For laboratory research use only. Not for human consumption. This article is general science education and is not medical advice.